OPEN CFDA 93.398 ↗ Competitive Grant Competitive ~100h typical effort
NCI

Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required)

🏛 National Institutes of Health (HHS-NIH11)

✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026

⏰ Deadline
Oct 14, 2026 in 89 days
📍 Scope
National

Can you apply?

This grant is for postdoctoral researchers and early-stage investigators pursuing independence in cancer research. Eligible applicants include postdoctoral fellows, clinical fellows, and recent PhD recipients (typically within 0–8 years of terminal degree) who will conduct clinical trials research within the U.S. or its territories. The award is designed to support a transition from mentored positions to independent investigator status through a structured two-phase approach: the K99 phase (2 years) provides mentored research support, and the R00 phase (3 years) supports transition to an independent tenure-track position. Applicants must have institutional sponsorship, strong mentoring plans, and commitment to developing an independent research career in cancer clinical trials.

Eligible applicants
Check your eligibility — what type of organization are you?

Not the right fit? Find grants for your organization in 5 questions →

Program description

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.
This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the ‘Independent Clinical Trial Not Allowed’ companion NOFO (PAR-23-286).

Who can apply

Eligible applicants

How to apply

Application links

Required documents

  • NIH Application Form (SF-424 R&R)
  • Project Narrative (Research Strategy, typically 12–15 pages)
  • Specific Aims (1–2 pages)
  • Significance and Innovation section
  • Approach section detailing clinical trial design and methodology
  • Mentoring Plan and letter of mentor support
  • Sponsor letter from department or division chair
  • Career Development Plan
  • Biographical Sketches (mentor and applicant)
  • Budget Justification
  • Budget Form (SF-424 R&R Budget)
  • Supporting Data and Appendices (as needed for clinical trial protocols or preliminary results)
  • Letters of Reference (typically 3–5 from established researchers)
  • Institutional Support documentation
  • NIH Conflict of Interest form

Program contact

Funding track record

Recent awards under CFDA 93.398 from the last 3 years — real organizations that won funding through this same program.

98
awards (3 yrs)
$870M
total funded
48
unique recipients
$8.9M
average award

Top 10 Largest Recent Awards

  1. $23,853,515
  2. $22,820,040
  3. $17,454,036
  4. $15,407,472
  5. $14,832,927
  6. $14,410,208
  7. $14,234,718
  8. $14,219,981
  9. $13,766,537
  10. $13,734,930

Top States by Funding

  • CA 14 awards $114.6M
  • MA 10 awards $104.9M
  • TX 9 awards $102.7M
  • NY 9 awards $65.8M
  • NC 6 awards $62.1M

Source: USAspending.gov — federal spending transparency. Data covers last 3 years.

Funding history

Annual funding for this program — Federal obligations (CFDA 93.398). How funding has trended year over year.

2024 $228,173,992
2025 $213,201,522
2026 est. $135,455,000

FAQ

Who is eligible to apply for the K99/R00 award?

Postdoctoral researchers and clinical fellows, typically within 0–8 years of earning a PhD, MD, or equivalent terminal degree. Foreign nationals on appropriate visas and U.S. citizens/permanent residents are eligible. Applicants must hold a doctoral degree and propose clinical trial research.

What is the two-phase structure of this award?

The K99 phase (2 years) provides mentored research support at the postdoctoral level. Upon transition criteria being met, the R00 phase (3 years) supports independent research at a new institution, typically as a tenure-track faculty member or equivalent independent position.

What research activities are supported?

This mechanism supports cancer research with a required clinical trials component. Research must involve direct interaction with human subjects or clinical data and must demonstrate potential for independent investigation in cancer science.

How competitive is this mechanism?

K99/R00 awards are highly competitive. Success rates typically range from 15–25%, depending on the specific funding year and research area. Strong mentorship, clear transition plans, and innovative research ideas are critical.

What is the typical funding range?

Annual budgets typically range from $75,000 to $150,000 depending on research requirements, research environment, and salary support. Total award across both phases can exceed $400,000 with indirect costs.

💡 Tips for applicants

  • Identify a strong mentor and sponsor institution early. The quality of mentorship is a major evaluation criterion; ensure your mentor has published and leads an active research program.
  • Develop a clear transition plan from mentored research (K99) to independence (R00). Describe specific milestones, publications, and grant applications that demonstrate your path to independence.
  • Design clinical trials components thoughtfully. Since clinical trial experience is required, clearly articulate how your research involves human subjects or translational clinical data and why this is essential to your research agenda.
  • Align your research with NCI priorities. Review current NCI strategic initiatives and funding announcements to ensure your proposal addresses recognized research gaps in cancer clinical research.
  • Submit a competitive Specific Aims section. In 1–2 pages, clearly articulate the clinical or translational significance, innovation, and feasibility of your proposed research with preliminary data supporting key hypotheses.

⚠️ Common mistakes

Applications are often rejected when mentoring plans lack detail or when mentors have insufficient research funding and publication records to credibly supervise the fellow. Another frequent weakness is unclear or unrealistic transition plans—applicants must demonstrate concrete steps to independence (e.g., grant submissions, publications, faculty position searches) rather than vague statements. Finally, proposals that do not clearly integrate clinical trial components or that focus purely on bench science without translational relevance to clinical practice often fail to meet the specific intent of this mechanism.

Similar grants

89 days left Oct 14, 2026
Apply →